Le Lézard
Classified in: Health
Subject: PDT

TSI Introduces the New PortaCount® Respirator Fit Tester, Providing Intelligent Fit Test Solutions


SHOREVIEW, Minn., Nov. 15, 2017 /PRNewswire/ -- TSI Incorporated, a global leader in respirator fit testing instrumentation, is pleased to introduce a new generation of PortaCount® Respirator Fit Testers. Combining the industry's best respirator fit test with industry-first features, the new PortaCount platform is designed to provide intelligent fit test solutions across your entire respiratory protection program.

Featuring real time FitChecktm Mode and fit test animations, the new PortaCount Fit Tester provides staff with a better understanding of how respirators fit while helping test administrators be more productive. PortaCount Fit Testers uniquely combine real-time and real-world measurements to advance respirator safety beyond what any other fit test can deliver. No other instrument can provide one consistent and objective testing experience across any respirator, from full-facepiece respirators to all N95 masks.

"Building on the PortaCount Fit Tester's long tradition of excellence, we're excited about the new tools that will help our customers enhance the safety of their employees while improving their fit test productivity," states Troy Tillman, TSI Business Director.

The new PortaCount Respirator Fit Tester is shipping now! Learn more at www.tsi.com/portacount4.

About TSI Incorporated

TSI Incorporated serves a global market by investigating, identifying and solving measurement problems. As an industry leader in the design and production of precision instruments, TSI partners with research institutions and customers around the world to set the standard for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection. With headquarters based in the U.S. and field offices throughout Europe and Asia, TSI has established a worldwide presence in the markets we serve. Every day, our dedicated employees turn research into reality.

Media contact:
Kate Franssen-Hansen
TSI Incorporated
6517655203
http://www.tsi.com

Source:  TSI Incorporated

 

SOURCE TSI Incorporated


These press releases may also interest you

at 10:02
Completion of Largest Capacity GMP Run Marks New Standard in Biologics Manufacturing
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....

at 10:00
Missing Indigenous children: a third review since the Act came into force
Minister Responsible for Relations with the First Nations and the Inuit Ian Lafrenière today submitted in the National Assembly the third annual report on the administration of the Act to authorize the communication of personal information to the...

at 10:00
Cobb Outpatient Detox Opens New Outpatient Drug and Alcohol Detox Facility in Marietta, GA
Cobb Outpatient Detox has opened a new facility in Marietta, GA, providing outpatient drug and alcohol detox services. The center aims to assist individuals in overcoming addiction while balancing their work and family commitments. Located near major...

at 10:00
PER PERSON HEALTH CARE SPENDING EXCEEDED $6,700 IN 2022
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
BioInnovation Institute & Science announce the launch of the Translational Medicine Prize for Innovations in Women´s Health and Gender Medicine
BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces the launch of the BII & Science Translational Medicine Prize for Innovations in Women´s Health and...

at 10:00
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented...

More news about Health...


News published on and distributed by: